Atypical skin manifestations during immune checkpoint blockage in coronavirus disease 2019–infected patients with lung cancer
Cargando...
Fecha
Título de la revista
Publicado en
Journal of Thoracic Oncology, 1556-0864, Vol. 20, 2020 p. 30543-30548
Publicado por
Elsevier
URL de la fuente
ISSN de la revista
Título del volumen
Resumen
Descripción
Abstract
A new coronavirus, named severe acute respiratory syndrome–coronavirus-2 by the WHO, has rapidly spread around the world since its first reported case in late December of 2019 from Wuhan, the People’s Republic of China. As of mid-April 2020, this virus has affected more than 180 countries and territories, infecting more than 1,650,000 individuals and causing over 100,000 deaths. With approximately 20 million new cases globally per year, cancer affects a substantial portion of the population. Individuals affected by cancer are more susceptible to infections owing to coexisting chronic diseases (cardiovascular, pulmonary, and diabetes), overall poor health status, and systemic immunosuppressive states caused by both cancer and the anticancer treatment. As a consequence, patients with malignancies, especially those with lung cancer who develop coronavirus disease 2019, experience more difficult outcomes. A recent multicenter study carried out by the Hubei Anti-Cancer Association has also documented that patients with lung cancer had an increased risk of death, intensive care unit requirement, risk of presenting severe or critical symptoms, and use of invasive mechanical ventilation. Here, we present two representative cases of patients with lung cancer and coronavirus disease 2019 without respiratory compromise and with atypical and severe skin manifestations—findings that could be influenced by the long-term use of anti–programmed cell death protein 1 antibody.
Palabras clave
Keywords
Anti–PD-1 therapy, COVID-19, Lung cancer, Erythema multiforme, Urticarial, Vasculitis